Farletuzumab

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a therapeutic humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer[1].

Research Areas >> Cancer

Farletuzumab (MORAb-003; 0-10 µg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1]. Farletuzumab (0.1-100 µg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro[1]. Farletuzumab (0-10 µg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway[1]. Cell Cytotoxicity Assay[1] Cell Line: IGROV-1 cells Concentration: 0.1, 1, 10, and 100 µg/mL Incubation Time: 1 hours Result: Had significant cytotoxicity at IGROV-1 cells.

[1]. Ebel W, et, al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007 Mar 9;7:6.